110 news items
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
AKRO
2 Jun 24
, materially influencing the study's potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY
Class Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc.
AKRO
1 Jun 24
materially misleading statements and omissions to the public, Akero's investors have suffered significant losses.If you suffered Akero losses
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
AKRO
31 May 24
to disclose material information during the Class Period, violating federal securities laws
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Akero Therapeutics, Inc. (AKRO)
AKRO
31 May 24
of Akero's materially misleading statements and omissions to the public, Akero's investors have suffered significant losses
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
AKRO
31 May 24
secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study's design, materially influencing the study's
p71z2dpwvifap1ryvb0tpin82bbt0ycb5wey4
AKRO
30 May 24
and in the calculation of the study's primary endpoint, Akero had introduced a confounding factor into the study's design, materially influencing the study's
yrjvikcyjr c6wz4tfogi5v9vlahzs3q4yy
AKRO
30 May 24
; (iv) Akero had introduced a confounding factor into the SYMMETRY study's design, materially influencing the study's potential results and increasing
xer4ezuu7zo9jz8hz7 9f2sjd
AKRO
30 May 24
, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Akero
6o71v765jew8tgu9903aw21lri9q4j6ilpm32hpt237qdcrhgbdahqlmb
AKRO
CMP
EXAI
30 May 24
in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose
x327w7 7jg9jea6ahu321s4xh44n
AKRO
29 May 24
executives are charged with failing to disclose material information during the Class Period, violating federal securities laws
svio0jui9jxf3zttp95lg1bhx7 ah1x2giy4s95ckxhxsfah9equrozx6
AKRO
29 May 24
factor into the SYMMETRY study's design, materially influencing the study's potential results and increasing the risks that the study would
dxbv1703zz14y1rpe3kr7yb502v0z5uwpspglc0alo
AKRO
29 May 24
materially misleading statements and omissions to the public, Akero's investors have suffered significant losses.If you suffered Akero losses
28o1gaa0vm4k2ev0fcahz6many7yzx0y5zmjvuy
ADSK
AKRO
CMP
29 May 24
' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant
6fg070rhbhyd3yxugwhxdipk7a5jw5is5xpqub
AKRO
29 May 24
and materially misleading throughout the class period. When the market learned the truth about Akero, investors suffered damages
cv5v3z5e3hv6jbe86ys7uw230atwd
AKRO
29 May 24
the Class Period Akero made statements that were materially false and misleading when made because the Company failed to disclose the following adverse
ssadl3us
AKRO
28 May 24
to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading
op0tbc7qfpz2s0bh121dtc2c3zi0qz2g7k gucynl8vm
AKRO
28 May 24
the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study's design, materially
8yfjsr6k43n7bzh7htgstm1rwe6mtcrcb 5i5
AKRO
28 May 24
. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false
8bb4q4dxkeo1hp4iun8l53cbfqbgjook7 b7hvw5l3x0ewz4w
AKRO
27 May 24
study's design, materially influencing the study's potential results and increasing the risks that the study would fail to meet its primary endpoint; (5
bztgdo6rexnmqi8oipzslnfh4fahrknrm5u6o
AKRO
24 May 24
Akero and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal